SFRP4 and Alzheimer disease: In our AD model, we could observe a clear and significant increase in the gene expression of the inhibitors of Wnt- β catenin pathway such as Glycogen Synthase Kinase 3 (GSK-3β) and Wnt antagonists sFRP4 while the expression of β-catenin was reduced (Figure 4a(i)).